Top

Published in:

Open Access 08-03-2024 | Paget's Disease of Bone

Osteocytes and Paget’s Disease of Bone

Authors: Hirofumi Tenshin, Jesus Delgado-Calle, Jolene J. Windle, G. David Roodman, John M. Chirgwin, Noriyoshi Kurihara

Published in: Current Osteoporosis Reports | Issue 2/2024

Abstract

Purpose of Review

To describe the contributions of osteocytes to the lesions in Paget’s disease, which are characterized by locally overactive bone resorption and formation.

Recent Findings

Osteocytes, the most abundant cells in bone, are altered in Paget’s disease lesions, displaying increased size, decreased canalicular length, incomplete differentiation, and less sclerostin expression compared to controls in both patients and mouse models. Pagetic lesions show increased senescent osteocytes that express RANK ligand, which drives osteoclastic bone resorption. Abnormal osteoclasts in Paget’s disease secrete abundant IGF1, which enhances osteocyte senescence, contributing to lesion formation.

Summary

Recent data suggest that osteocytes contribute to lesion formation in Paget’s disease by responding to high local IGF1 released from abnormal osteoclasts. Here we describe the characteristics of osteocytes in Paget’s disease and their role in bone lesion formation based on recent results with mouse models and supported by patient data.

• Singer FR. Paget’s disease of bone. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000. An excellent review of the history and clinical aspects of Paget’s disease of bone.

Roodman GD, Windle JJ. Paget disease of bone. J Clin Invest. 2005;115(2):200–8. https://doi.org/10.1172/jci24281.CrossRefPubMedPubMedCentral

Roodman GD, Kurihara N, Ohsaki Y, Kukita A, Hosking D, Demulder A, Smith JF, Singer FR. Interleukin 6. A potential autocrine/paracrine factor in Paget’s disease of bone. J Clin Invest. 1992;89(1):46–52. https://doi.org/10.1172/JCI115584.CrossRefPubMedPubMedCentral

Galson DL, Roodman GD. Pathobiology of Paget’s disease of bone. J Bone Metab. 2014;21(2):85–98. https://doi.org/10.11005/jbm.2014.21.2.85.CrossRefPubMedPubMedCentral

Teramachi J, Zhou H, Subler MA, Kitagawa Y, Galson DL, Dempster DW, Windle JJ, Kurihara N, Roodman GD. Increased IL-6 expression in osteoclasts is necessary but not sufficient for the development of Paget’s disease of bone. J Bone Miner Res. 2014;29(6):1456–65. https://doi.org/10.1002/jbmr.2158.CrossRefPubMed

Cundy T, Maslowski K, Grey A, Reid IR. Durability of response to zoledronate treatment and competing mortality in Paget’s disease of bone. J Bone Miner Res. 2017;32(4):753–6. https://doi.org/10.1002/jbmr.3029.CrossRefPubMed

• Delgado-Calle J, Bellido T. The osteocyte as a signaling cell. Physiol Rev. 2022;102(1):379–410. https://doi.org/10.1152/physrev.00043.2020. Up-to-date review of osteocyte signaling, which provides major contributions to Paget’s disease of bone.CrossRefPubMed

• Gennari L, Rendina D, Merlotti D, Cavati G, Mingiano C, Cosso R, Materozzi M, Pirrotta F, Abate V, Calabrese M, Falchetti A. Update on the pathogenesis and genetics of Paget’s disease of bone. Front Cell Dev Biol. 2022;10:932065. https://doi.org/10.3389/fcell.2022.932065. A clear recent summary of environmental and genetic causes of Paget’s disease of bone.CrossRefPubMedPubMedCentral

Ling Z, Aini H, Kajikawa S, Shirakawa J, Tsuji K, Asou Y, Koga H, Sekiya I, Nifuji A, Noda M, Ezura Y. Osteolytic bone loss and skeletal deformities in a mouse model for early-onset Paget’s disease of bone with PFN1 mutation are treatable by alendronate. Pharmaceuticals (Basel). 2023;16(10):1395. https://doi.org/10.3390/ph16101395.CrossRefPubMedPubMedCentral

10.

• Kurihara N, Hiruma Y, Yamana K, Michou L, Rousseau C, Morissette J, Galson DL, Teramachi J, Zhou H, Dempster DW, Windle JJ, Brown JP, Roodman GD. Contributions of the measles virus nucleocapsid gene and the SQSTM1/p62(P392L) mutation to Paget’s disease. Cell Metab. 2011;13(1):23–34. https://doi.org/10.1016/j.cmet.2010.12.002. An important demonstration of MVNP and p62 effects on mouse models of Paget’s bone disease.

11.

Daroszewska A, van Hof RJ, Rojas JA, Layfield R, Landao-Basonga E, Rose L, Rose K, Ralston SH. A point mutation in the ubiquitin-associated domain of SQSMT1 is sufficient to cause a Paget’s disease-like disorder in mice. Hum Mol Genet. 2011;20(14):2734–44. https://doi.org/10.1093/hmg/ddr172.CrossRefPubMed

12.

Gallone S, Di Stefano M, Rainero I, Fenoglio P, Gravante E, Incardona S, Acutis PL, Maniaci MG, Isaia GC, Pinessi L. Detection of exon 8 mutations in sqstm1/p62 gene by mutation-specific restriction enzyme digestion: a sensitive screening for Paget disease of bone. Panminerva Med. 2011;53(1):71–2.PubMed

13.

Menaa C, Reddy SV, Kurihara N, Maeda H, Anderson D, Cundy T, Cornish J, Singer FR, Bruder JM, Roodman GD. Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget’s disease of bone. J Clin Invest. 2000;105(12):1833–8. https://doi.org/10.1172/jci9133.CrossRefPubMedPubMedCentral

14.

Teramachi J, Nagata Y, Mohammad K, Inagaki Y, Ohata Y, Guise T, Michou L, Brown JP, Windle JJ, Kurihara N, Roodman GD. Measles virus nucleocapsid protein increases osteoblast differentiation in Paget’s disease. J Clin Invest. 2016;126(3):1012–22. https://doi.org/10.1172/JCI82012.CrossRefPubMedPubMedCentral

15.

Boock V, Roy B, Pfeffer G, Kimonis V. Therapeutic developments for valosin-containing protein mediated multisystem proteinopathy. Curr Opin Neurol. 2023;36(5):432–40. https://doi.org/10.1097/WCO.0000000000001184.CrossRefPubMed

16.

Huybrechts Y, De Ridder R, Steenackers E, Devogelaer JP, Mortier G, Hendrickx G, Van Hul W. Genetic screening of ZNF687 and PFN1 in a Paget’s disease of bone cohort indicates an important role for the nuclear localization signal of ZNF687. Calcif Tissue Int. 2023;113(5):552–7. https://doi.org/10.1007/s00223-023-01137-5.CrossRefPubMed

17.

Siris ES, Roodman GD. Paget’s disease of bone. In: Rosen CJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. 8th ed. Washington DC: American Society for Bone and Mineral Research: Wiley-Blackwell; 2013.659-68.

18.

Harvey L, Gray T, Beneton MN, Douglas DL, Kanis JA, Russell RG. Ultrastructural features of the osteoclasts from Paget’s disease of bone in relation to a viral aetiology. J Clin Pathol. 1982;35(7):771–9. https://doi.org/10.1136/jcp.35.7.771.CrossRefPubMedPubMedCentral

19.

Basle MF, Rebel A, Fournier JG, Russell WC, Malkani K. On the trail of paramyxoviruses in Paget’s disease of bone. Clin Orthop Relat Res. 1987;217:9–15.CrossRef

20.

Helfrich MH, Hobson RP, Grabowski PS, Zurbriggen A, Cosby SL, Dickson GR, Fraser WD, Ooi CG, Selby PL, Crisp AJ, Wallace RG, Kahn S, Ralston SH. A negative search for a paramyxoviral etiology of Paget’s disease of bone: molecular, immunological, and ultrastructural studies in UK patients. J Bone Miner Res. 2000;15(12):2315–29. https://doi.org/10.1359/jbmr.2000.15.12.2315.CrossRefPubMed

21.

•• Kurihara N, Zhou H, Reddy SV, Garcia Palacios V, Subler MA, Dempster DW, Windle JJ, Roodman GD. Expression of measles virus nucleocapsid protein in osteoclasts induces Paget’s disease-like bone lesions in mice. J Bone Miner Res. 2006;21(3):446–55. https://doi.org/10.1359/JBMR.051108. First demonstration that MVNP targeted to osteoclasts could induce Paget’s disease of bone in mice.

22.

Miyagawa K, Ohata Y, Delgado-Calle J, Teramachi J, Zhou H, Dempster DD, Subler MA, Windle JJ, Chirgwin JM, Roodman GD, Kurihara N. Osteoclast-derived IGF1 is required for pagetic lesion formation in vivo. JCI Insight. 2020;5(6):e133113. https://doi.org/10.1172/jci.insight.133113.CrossRefPubMedPubMedCentral

23.

•• Miyagawa K, Tenshin H, Mulcrone PL, Delgado-Calle J, Subler MA, Windle JJ, Chirgwin JM, Roodman GD, Kurihara N. Osteoclast-derived IGF1 induces RANKL production in osteocytes and contributes to pagetic lesion formation. JCI Insight. 2023;8(14):e159838. https://doi.org/10.1172/jci.insight.159838. Demonstration that osteoclast-derived IGF1 acts on osteocytes, contributing to pagetic lesions in mice.CrossRefPubMedPubMedCentral

24.

Wang FM, Sarmasik A, Hiruma Y, Sun Q, Sammut B, Windle JJ, Roodman GD, Galson DL. Measles virus nucleocapsid protein, a key contributor to Paget’s disease, increases IL-6 expression via down-regulation of FoxO3/Sirt1 signaling. Bone. 2013;53(1):269–76. https://doi.org/10.1016/j.bone.2012.12.007.CrossRefPubMed

25.

Bellido T, Borba VZ, Roberson P, Manolagas SC. Activation of the Janus kinase/STAT (signal transducer and activator of transcription) signal transduction pathway by interleukin-6-type cytokines promotes osteoblast differentiation. Endocrinology. 1997;138(9):3666–76. https://doi.org/10.1210/endo.138.9.5364.CrossRefPubMed

26.

Wu Q, Zhou X, Huang D, Ji Y, Kang F. IL-6 enhances osteocyte-mediated osteoclastogenesis by promoting JAK2 and RANKL activity in vitro. Cell Physiol Biochem. 2017;41(4):1360–9. https://doi.org/10.1159/000465455.CrossRefPubMed

27.

Mills BG, Frausto A. Cytokines expressed in multinucleated cells: Paget’s disease and giant cell tumors versus normal bone. Calcif Tissue Int. 1997;61(1):16–21. https://doi.org/10.1007/s002239900285.CrossRefPubMed

28.

Neale SD, Smith R, Wass JA, Athanasou NA. Osteoclast differentiation from circulating mononuclear precursors in Paget’s disease is hypersensitive to 1,25-dihydroxyvitamin D₃ and RANKL. Bone. 2000;27(3):409–16. https://doi.org/10.1016/s8756-3282(00)00345-8.CrossRefPubMed

29.

Florencio-Silva R, Sasso GR, Sasso-Cerri E, Simões MJ, Cerri PS. Biology of bone tissue: structure, function, and factors that influence bone cells. Biomed Res Int. 2015;2015:421746. https://doi.org/10.1155/2015/421746.CrossRefPubMedPubMedCentral

30.

Belanger LF, Jarry L, Uhthoff HK. Osteocytic osteolysis in Paget’s disease. Rev Can Biol. 1968;27(1):37–44.PubMed

31.

Singer FR, Mills BG, Gruber HE, Windle JJ, Roodman GD. Ultrastructure of bone cells in Paget’s disease of bone. J Bone Miner Res. 2006;21(Suppl 2):51–4. https://doi.org/10.1359/jbmr.06s209.CrossRef

32.

Yavropoulou MP, van Lierop AH, Hamdy NA, Rizzoli R, Papapoulos SE. Serum sclerostin levels in Paget’s disease and prostate cancer with bone metastases with a wide range of bone turnover. Bone. 2012;51(1):153–7. https://doi.org/10.1016/j.bone.2012.04.016.CrossRefPubMed

33.

Idolazzi L, Fassio A, Tripi G, Braga V, Viapiana O, Adami G, Rossini M, Gatti D. Circulating Dickkopf-1 and sclerostin in patients with Paget’s disease of bone. Clin Rheumatol. 2017;36(4):925–8. https://doi.org/10.1007/s10067-016-3497-1.CrossRefPubMed

34.

Chen L, Gao G, Shen L, Yue H, Zhang G, Zhang Z. Serum sclerostin and its association with bone turnover marker in metabolic bone diseases. Dis Markers. 2022;2022:7902046. https://doi.org/10.1155/2022/7902046.CrossRefPubMedPubMedCentral

35.

Bonewald LF. The amazing osteocyte. J Bone Miner Res. 2011;26(2):229–38. https://doi.org/10.1002/jbmr.320.CrossRefPubMed

36.

Delgado-Calle J, Anderson J, Cregor MD, Hiasa M, Chirgwin JM, Carlesso N, Yoneda T, Mohammad KS, Plotkin LI, Roodman GD, Bellido T. Bidirectional Notch signaling and osteocyte-derived factors in the bone marrow microenvironment promote tumor cell proliferation and bone destruction in multiple myeloma. Cancer Res. 2016;76(5):1089–100. https://doi.org/10.1158/0008-5472.CAN-15-1703.CrossRefPubMedPubMedCentral

37.

Montesi M, Jahn K, Bonewald L, Stea S, Bordini B, Beraudi A. Hypoxia mediates osteocyte ORP150 expression and cell death in vitro. Mol Med Rep. 2016;14(5):4248–54. https://doi.org/10.3892/mmr.2016.5790.CrossRefPubMed

38.

Guo D, Keightley A, Guthrie J, Veno PA, Harris SE, Bonewald LF. Identification of osteocyte-selective proteins. Proteomics. 2010;10(20):3688–98. https://doi.org/10.1002/pmic.201000306.CrossRefPubMedPubMedCentral

39.

Robling AG, Bonewald LF. The osteocyte: new insights. Annu Rev Physiol. 2020;82:485–506. https://doi.org/10.1146/annurev-physiol-021119-034332.CrossRefPubMedPubMedCentral

40.

Qiu T, Crane JL, Xie L, Xian L, Xie H, Cao X. IGF-I induced phosphorylation of PTH receptor enhances osteoblast to osteocyte transition. Bone Res. 2018;6:5. https://doi.org/10.1038/s41413-017-0002-7.CrossRefPubMedPubMedCentral

41.

•• Farr JN, Fraser DG, Wang H, Jaehn K, Ogrodnik MB, Weivoda MM, Drake MT, Tchkonia T, LeBrasseur NK, Kirkland JL, Bonewald LF, Pignolo RJ, Monroe DG, Khosla S. Identification of senescent cells in the bone microenvironment. J Bone Miner Res. 2016;31(11):1920–9. https://doi.org/10.1002/jbmr.2892. Detailed characterization of senescence in bone cells including osteocytes.CrossRefPubMed

42.

Tran D, Bergholz J, Zhang H, He H, Wang Y, Zhang Y, Li Q, Kirkland JL, Xiao ZX. Insulin-like growth factor-1 regulates the SIRT1-p53 pathway in cellular senescence. Aging Cell. 2014;13(4):669–78. https://doi.org/10.1111/acel.12219.CrossRefPubMedPubMedCentral

43.

McManus S, Roux S. The adaptor protein p62/SQSTM1 in osteoclast signaling pathways. J Mol Signal. 2012;7:1. https://doi.org/10.1186/1750-2187-7-1.CrossRefPubMedPubMedCentral

44.

•• Kim HN, Xiong J, MacLeod RS, Iyer S, Fujiwara Y, Cawley KM, Han L, He Y, Thostenson JD, Ferreira E, Jilka RL, Zhou D, Almeida M, O’Brien CA. Osteocyte RANKL is required for cortical bone loss with age and is induced by senescence. JCI Insight. 2020;5(19):e138815. https://doi.org/10.1172/jci.insight.138815. Important insight into RANKL expression in senescent osteocytes.CrossRefPubMedPubMedCentral

45.

• Yan M, Tsukasaki M, Muro R, Ando Y, Nakamura K, Komatsu N, Nitta T, Okamura T, Okamoto K, Takayanagi H. Identification of an intronic enhancer regulating RANKL expression in osteocytic cells. Bone Res. 2023;11(1):43. https://doi.org/10.1038/s41413-023-00277-6. Identification of a transcriptional mechanism for regulation of RANKL in osteocytes.CrossRefPubMedPubMedCentral

Title: Osteocytes and Paget’s Disease of Bone
Authors: Hirofumi Tenshin
Jesus Delgado-Calle
Jolene J. Windle
G. David Roodman
John M. Chirgwin
Noriyoshi Kurihara
Publication date: 08-03-2024
Publisher: Springer US
Keyword: Paget's Disease of Bone
Published in: Current Osteoporosis Reports / Issue 2/2024
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI: https://doi.org/10.1007/s11914-024-00863-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Osteocytes and Paget’s Disease of Bone

Abstract

Purpose of Review

Recent Findings

Summary

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 2/2024

Regulation of FGF23 Production in Osteocytes

Correction: Practical Compass of Single-Cell RNA-Seq Analysis

Interfacial Tissue Regeneration with Bone

Neutrophils in Inflammatory Bone Diseases

Diagnosing Osteoporosis in Diabetes—A Systematic Review on BMD and Fractures

Extracellular Vesicles and Exosomes in the Control of the Musculoskeletal Health